| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Due from related parties | - | 0 |
| Net cash used in operating activities | -8,484,617 | -5,000,253 |
| Net proceeds from the sale of stock and exercise of warrants | 13,618,718 | 10,758,802 |
| Shares withheld to pay taxes on stock-based compensation | 10,404 | 10,404 |
| Payment of finance lease obligation | 6,602 | 2,850 |
| Settlement of stock award | - | 0 |
| Net cash provided by financing activities | 13,601,712 | 10,745,548 |
| Net increase (decrease) in cash and cash equivalents | 5,117,095 | 5,745,295 |
| Cash and cash equivalents at beginning of period | 1,191,325 | - |
| Cash and cash equivalents at end of period | 6,308,420 | - |
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)